Why Globus Medical, Inc. (GMED) stock moved
Globus Medical, Inc. (GMED) shares fell 0.0% to $85.90 as of August 15, 2026, a slight decline from the prior close of $85.94. BestStocks flagged the session as a major change for GMED. No single company-specific catalyst was confirmed during the move window. Below, we break down what changed for GMED, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
GMED fell 0.0% to $85.90
GMED fell 0.0% in its latest session, moving from $85.94 to $85.90.
What it means for Globus Medical, Inc. investors
For Globus Medical, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Earnings beat — stock sold off (sell-the-news reaction); Globus Medical, Inc. (GMED) moved +5.55% from $81.62 to $86.15 on 2026-08-10, reaching a new 30-day high on modestly elevated volume (1.7x the 5-day average). Weighing against that: Negative session, down 0.0%; Globus Medical, Inc. (GMED) moved -6.55% from $88.12 to $82.35 on 2026-08-07. Wall Street's consensus price target sits at $98.88, implying +15.1% upside from $85.90. BestStocks rates the overall signal quality weak (29/100). With earnings roughly 82 days out, the next report is the most likely near-term test of the move.
GMED price reaction
GMED last traded at $85.90, down $0.04 (-0.05%) from the previous close of $85.94. The session traded on 0.4× average volume (below avg), so participation was unremarkable.
Bullish and bearish analyst opinions on Globus Medical, Inc. (GMED)
The consensus analyst price target on Globus Medical, Inc. (GMED) is $98.88, 15.1% above the recent $85.90. Over the past 90 days analysts logged 0 upgrades, 5 maintains, and 0 downgrades. Here is how the bullish and bearish cases on GMED line up.
The bullish case
- Wall Street's consensus price target of $98.88 implies +15.1% upside from $85.90.
- The Street's most bullish target is $117.00 (+36.2%).
- Earnings beat — stock sold off (sell-the-news reaction).
- Globus Medical, Inc. (GMED) moved +5.55% from $81.62 to $86.15 on 2026-08-10, reaching a new 30-day high on modestly elevated volume (1.7x the 5-day average).
The bearish case
- The most bearish analyst target is $80.00 (-6.9%).
- Negative session, down 0.0%.
- Globus Medical, Inc. (GMED) moved -6.55% from $88.12 to $82.35 on 2026-08-07.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Aug 15, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for GMED
Frequently asked questions about GMED
Why did Globus Medical, Inc. (GMED) stock move?
GMED fell 0.0% to $85.90. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did GMED stock fall?
GMED lost 0.05% ($0.04) versus the prior close of $85.94, last trading at $85.90 on 0.4× average volume.
When is Globus Medical, Inc.'s next earnings date?
GMED's next earnings report is estimated for 2026-11-05 — about 82 days away.
What is the analyst price target for GMED?
The consensus analyst price target for GMED is $98.88, about 15.1% above the current $85.90. Over the past 90 days, analysts recorded 0 upgrades, 5 maintains, and 0 downgrades.
How BestStocks tracks GMED
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared GMED-specific materiality thresholds, triggering an evidence check. It draws on 18 tracked change events for GMED, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 15, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.